Actionable Strategies in Community Oncology to Achieve Equity in Triple-Negative Breast Cancer
Would you like to host a complimentary Grand Rounds presentation for members of the community oncology interprofessional team, including physicians, physician associates (PAs), nurse practitioners (NPs), pharmacists, and nurses at your facility?
- 1-hour presentation providing up to 1.0 ACCME/ANCC/ACPE/AAPA IPCE credit
- There is no fee to host this activity, and complimentary meeting materials will be provided
- Available May 1, 2023–December 15, 2023
For more information, contact Ashley Lilly at email@example.com
Physicians, physician associates (PAs), nurse practitioners (NPs), pharmacists, nurses specializing in oncology and practice in a community setting.
- Employ strategies to promote equitable care and outcomes for all patients with TNBC.
- Evaluate clinical trial data for ADCs as part of the evolving and expanding TNBC treatment calculus, including recent FDA approvals and updated guideline recommendations.
- Incorporate evidence-based treatment plans with an emphasis on the placement of novel therapeutics as part of equitable care for patients with TNBC.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from Gilead Sciences, Inc.
5 mins Introductions
15 mins Delineating the Disparity in Triple-negative Breast Cancer (TNBC): The Interface of Disease-state Complexity and Social Inequity
15 mins Demystifying Antibody-drug Conjugates (ADCs): Practical Approaches to Embracing Change in the Evolving TNBC Paradigm
15 mins Closing the TNBC Outcomes Chasm: Case-based Challenges for the Community Oncologist and Their Interprofessional Team
5 mins SMART Goals/Conclusions
5 mins Q&A
Sara Tolaney, MD, MPH (Chair)
Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Susan F. Smith Center for Women’s Cancers
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Sara Tolaney, MD, MPH–reports the following financial relationships: Consultant to 4D pharma plc; Aadi Biosciences; Arch Therapeutics, Inc.; AstraZeneca; Athenex, Inc.; Bayer; BeyondSpring Inc.; Blueprint Medicines Corporation; Bristol Myers Squibb Company; Certara, Inc.; Chugai Pharma USA, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Eli Lilly and Company; Ellipses Pharma; Genentech, Inc./Roche; Gilead Sciences, Inc.; Infinity Therapeutics; Menarini/Stemline Therapeutics, Inc.; Merck & Co., Inc.; Mersana therapeutics; Myovant Sciences; Novartis Pharmaceuticals Corporation; Odonate Therapeutics, Inc.; OncoSec Medical Inc.; OncXerna Therapeutics, Inc.; Pfizer Inc.; Sanofi; Seattle Genetics; Inc.; Reveal Genomics; Umoja Biopharma; Zentalis Pharmaceuticals; Zetagen; and Zymeworks Inc. Research Support (paid to institution) from AstraZeneca; Bristol Myers Squibb Company; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./Roche; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString; Nektar; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sanofi and Seattle Genetics, Inc.
Information to come
Information to come
Katherine A. Lee, PharmD, MPH–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1 hour of Interprofessional Continuing Education (IPCE) credit for learning and change.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to PAs: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education.
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-23-006-L01-P)
This activity is designated for 1.0 contact hour.
- 1.00 AAPA Category I CME
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 IPCE
- 1.00 Participation